Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Patient plan: look up a medication list

PANTOPRAZOLE SODIUM

All products: Limited Use (codes 293, 295, 297, 401, 402)

Other products in the same Health Canada class (A02BC) — coverage varies; not interchangeable

  • Pantoprazole (Tecta): general benefit
  • Rabeprazole (Pariet): general benefit
  • Lansoprazole (Prevacid): limited Use 293, 295, 297, 401, 402
  • Omeprazole (Losec DR Tab): limited Use 293, 297, 401, 402, Not a benefit
  • Dexlansoprazole (Dexilant): not a benefit
  • Esomeprazole (Nexium DR Tab): not a benefit

7 more in the class list below

Pantoloc · DIN 02229453 · 40mg · enteric-coated tablet

Limited Use — Reason for Use code 293, 295, 297, 401, 402 requiredMarketed · checked 2026-09-02
StatusLimited Use — Reason for Use code 293, 295, 297, 401, 402 required
Write on scriptLU code 293, 295, 297, 401, 402 (patient must meet the criteria below)
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Ontario Limited Use criteria — code 293, 295, 297, 401, 402
Reason for Use code 293 Gastroesophageal Reflux Disease (GERD) For the treatment of erosive GERD or upper GI malignancy; OR For the treatment of non-erosive GERD after failure of H2-receptor antagonist therapy. Patients with GERD should be reassessed within 6 months after initial treatment with a PPI. The reassessment could include confirmation of need for PPI with endoscopy, a trial of PPI withdrawal, or step-down therapy to H2-receptor antagonist therapy. Note: There is a lack of published evidence to support double-dose PPI therapy in this setting. Coverage limit: LU Authorization Period: 1 year Reason for Use code 295 H. pylori-positive Peptic Ulcers For the treatment of H. pylori-positive peptic ulcers where H. pylori is documented, by serology, urea breath test or endoscopy, for a course of up to 14 days in combination with antimicrobial therapy. Retreatment of H. pylori-positive peptic ulcers must be documented by persistent H. pylori infection on urea breath test or endoscopy. Maximum duration: 14 days (for retreatment, a four-week period must elapse since the end of the previous treatment). Coverage limit: LU Authorization Period: 1 year Reason for Use code 297 Confirmed Peptic Ulcers or NSAID-induced Ulcer Prophylaxis: For the treatment of confirmed peptic ulcers and NSAID-induced ulcers; OR For the prophylaxis of NSAID-induced ulcers for patients at increased risk of GI bleeding. Note: There is a lack of published evidence to support double-dose PPI therapy in this setting. Coverage limit: LU Authorization Period: 1 year Reason for Use code 401 Other Gastrointestinal Disorders: For the treatment of gastroduodenal Crohns disease, short-gut syndrome, scleroderma, or pancreatitis. Note: There is a lack of published evidence to support double-dose PPI therapy in these settings. Coverage limit: LU Authorization Period: 1 year Reason for Use code 402 Severe Conditions: For the treatment of severe esophagitis, Zollinger-Ellison syndrome, esophageal stricture, persistent symptoms of GERD or persistent erosive esophagitis, or upon hospital discharge following a gastrointestinal bleed. For patients receiving double-dose therapy, the need to continue treatment at higher doses should be reassessed after eight weeks. For re-treatment at higher doses, a four-week period should have elapsed from the end of the previous treatment. Reassessment could include a procedural assessment of the condition or step-down therapy to lower-dose proton pump inhibitor (PPI) therapy. Coverage limit: LU Authorization Period: 1 year
Savings card: RxHelp ONE lists Pantoloc (read 2026-09-10) — brand-name savings card, free; cannot be combined with another card on the same claim. (rxhelp.ca ↗)
1 brand, same coverage
Pantoloc · DIN 02229453 Manufacturer: Nycomed Canada Inc.; listing date 1997-08-28 Health Canada: Marketed since 2013-01-09 · brand PANTOLOC · ATC A02BC02 PANTOPRAZOLE · form Tablet (enteric-coated) · route Oral · ingredients PANTOPRAZOLE (PANTOPRAZOLE SODIUM) 40 MG · company Takeda canada inc · schedule Prescription
Check this DIN again · Health Canada product record

Ministry pays: $0.2016 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=47339 · Verify on the e-Formulary ↗ (DIN 02229453)

Source record
DIN 02229453: Pantoloc Raw flags: chronicUseMed=Y, sec12=Y, sec3=Y Item: 564000080; group id 694; item number 1716; lccId 00106; manufacturer id NYC Source form: Ent Tab; strength: 40mg Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): $2.0803; ministry $0.2016 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02229453 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=47339
Interchangeable products
AG-Pantoprazole Sodium · DIN 02481588 · $0.2016 Apo-Pantoprazole · DIN 02292920 · $0.2016 Auro-Pantoprazole · DIN 02415208 · $0.2016 Bio-Pantoprazole · DIN 02445867 · $0.2016 Co Pantoprazole · DIN 02300486 · $0.2016 Jamp Pantoprazole Sodium · DIN 02392623 · $0.2016 Jamp-Pantoprazole · DIN 02357054 · $0.2016 M-Pantoprazole · DIN 02467372 · $0.2016 Mar-Pantoprazole · DIN 02416565 · $0.2016 Mint-Pantoprazole · DIN 02417448 · $0.2016 NRA-Pantoprazole · DIN 02471825 · $0.2016 PMS-Pantoprazole · DIN 02307871 · $0.2016 Pantoprazole · DIN 02370808 · $0.2016 Pantoprazole · DIN 02428180 · $0.2016 Pantoprazole · DIN 02431327 · $0.2016 Pantoprazole · DIN 02547368 · $0.2016 Ran-Pantoprazole · DIN 02305046 · $0.2016 Sandoz Pantoprazole · DIN 02301083 · $0.2016 Teva-Pantoprazole · DIN 02285487 · $0.2016
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02229453
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Other drugs in the same formulary class (56:40 Miscellaneous G.I. Drugs) and how they are covered

Matched class: 56:40 Miscellaneous G.I. Drugs

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Covered without a code on the Ontario formulary: BUDESONIDE, MESALAZINE, NIZATIDINE, OLSALAZINE SODIUM, PANTOPRAZOLE MAGNESIUM, RABEPRAZOLE SODIUM, SUCRALFATE Some products covered without a code (check the product listing): 5-AMINOSALICYLIC ACID, CIMETIDINE, DOMPERIDONE MALEATE, FAMOTIDINE, LACTULOSE, METOCLOPRAMIDE HCL, MISOPROSTOL, RANITIDINE HCL 56:40 Miscellaneous G.I. Drugs

PANTOPRAZOLE MAGNESIUM

· 6 products · General benefit · strengths: 40mg · Ent Coated Tab

RABEPRAZOLE SODIUM

· 16 products · General benefit · strengths: 10mg, 20mg · Tab

LANSOPRAZOLE

· 16 products · Limited Use, codes 293, 295, 297, 401, 402 · strengths: 15mg, 30mg · DR Cap

OMEPRAZOLE

· 19 products · Off-Formulary Interchangeable, not an ODB benefit (4), Listed, not a benefit (2), Limited Use, codes 293, 297, 401, 402 (13) · strengths: 10mg, 20mg · DR Cap

DEXLANSOPRAZOLE

· 6 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 30mg, 60mg · DR Cap

ESOMEPRAZOLE

· 22 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 40mg, 20mg · DR Tab

CIMETIDINE

· 10 products · General benefit (5), Listed, not a benefit (5) · strengths: 200mg, 300mg, 400mg, 600mg, 800mg · Tab

FAMOTIDINE

· 16 products · Listed, not a benefit (2), General benefit (14) · strengths: 20mg, 40mg · Tab

MISOPROSTOL

· 4 products · Listed, not a benefit (2), General benefit (2) · strengths: 100mcg, 200mcg · Tab

NIZATIDINE

· 2 products · General benefit · strengths: 150mg, 300mg · Cap

RANITIDINE HCL

· 23 products · Listed, not a benefit (3), General benefit (20) · strengths: 15mg/mL, 150mg, 300mg · Oral Sol, Tab

SUCRALFATE

· 4 products · General benefit · strengths: 1g/5mL, 1g · Oral Susp, Tab Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26; class 56:40 and 10 more
Full class listing Related classes: 56:04 Antacids and Adsorbents, 56:08 Antidiarrhea Agents, 56:12 Cathartics, 56:16 Digestants, 56:22 Antiemetics and Antinauseants Same formulary class, not same indication: class membership alone does not establish equivalent uses.
What the Health Canada label says it is for
1 INDICATIONS PANTOLOC® (pantoprazole sodium) is indicated for the treatment of conditions where a reduction of gastric acid secretion is required, such as the following: • Duodenal ulcer • Gastric ulcer • Reflux esophagitis • Symptomatic gastro-esophageal reflux disease (such as, acid regurgitation and heartburn) • Prevention of gastrointestinal lesions induced by non-steroidal anti-inflammatory drugs (NSAIDs) in patients with a need for continuous NSAID treatment, who have increased risk to develop NSAID-associated upper gastrointestinal lesions • Helicobacter pylori (H. pylori) associated duodenal ulcer Pantoprazole, in combination with clarithromycin and either amoxicillin or metronidazole, is indicated for the treatment of patients with an active duodenal ulcer who are H. pylori positive (see 4 DOSAGE AND ADMINISTRATION and 14 CLINICAL TRIALS). 1.1 Pediatrics Pediatrics (< 18 years of age): No data are available to Health Canada; therefore, Health Canada has not authorized an indication for pediatric use. 1.2 Geriatrics Geriatrics (> 65 years of age): Based on the data submitted and reviewed by Health Canada, the safety and e… https://pdf.hres.ca/dpd_pm/00070179.PDF PM date: MAR 30, 2023 Source product: PANTOLOC; DIN 02229453; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.